Rivaroxaban
35 NDCs across 12 manufacturers|20 Generic,15 Brand
Rivaroxaban is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 1, 2011, and the first generic was approved Mar 3, 2025. FDA's Orange Book lists 68 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $6.2 billion on Rivaroxaban across 6.7 million claims for 1.3 million beneficiaries.
Rivaroxaban is available as 35 NDCs from 12 manufacturers (20 generic, 15 brand), with NADAC prices from $0.65 to $19.54 per EA — the most expensive product costs about 30× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
35
20G / 15B
Manufacturers
12
competing in market
Price Spread
$0.65 – $19.54
per EA, 33 of 35 NDCs
7d Activity
avg -0.5% WoW · of 35 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Janssen Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Factor Xa Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
12 manufacturers producing RIVAROXABAN(2 pricing outliers)
Frequently Asked Questions
What is Rivaroxaban used to treat?
Rivaroxaban is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
When did Rivaroxaban become available as a generic?
FDA approved the first generic Rivaroxaban (ANDA) on Mar 3, 2025. The Orange Book currently lists 68 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rivaroxaban?
In 2024, Medicare Part D spent $6.2 billion on Rivaroxaban across 6.7 million claims for 1.3 million beneficiaries.
How many Rivaroxaban products are on the market?
The Rivaroxaban drug market contains 35 NDCs from 12 manufacturers — 20 generic and 15 brand products.
What is the price range for Rivaroxaban?
NADAC reference prices for Rivaroxaban range from $0.6496 to $19.5419 per EA — the most expensive product costs about 30× the cheapest. 2 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Rivaroxaban cheaper than brand?
The average generic NADAC for Rivaroxaban is $0.6496 per EA, versus $17.4379 for brand-labeled products — brand versions average about 27× the generic price.
Which manufacturers make Rivaroxaban?
12 manufacturers list Rivaroxaban in NADAC. Ranked by number of NDCs, the largest are Janssen Pharmaceuticals Inc. (15), ScieGen Pharmaceuticals Inc. (2), Dr. Reddy's Laboratories Inc. (2), Macleods Pharmaceuticals Limited (2), Sun Pharmaceutical Industries Inc. (2).
How has the price of Rivaroxaban changed recently?
Over the past 7 days, 6 Rivaroxaban NDCs rose and 28 fell, with a market-wide average change of -0.5%.